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Abstract
Background: Despite various culotte-based stenting techniques available clinically, the 
optimal one remains undetermined. The study aimed to test whether ex vivo mono-ring 
culotte stenting (MRC) was technically feasible and superior to mini culotte stenting (MCS) 
in treatment of coronary bifurcation lesions.
Methods: Mono-ring culotte stenting was characterized by ex vivo wiring of the most proxi-
mal cell of the side branch (SB) stent to ensure a mono-ring result of the culotte stenting. 
Comparison of MRC vs. MCS in treatment of true bifurcation lesions was performed in vitro 
(n = 15 for each group) and in clinical case-controlled study with propensity matching at  
a ratio of 1:2 (n = 21 for MRC group; n = 42 for MCS group).
Results: Compared to MCS, MRC had lower incidence of stent under-expansion band (0% 
vs. 53.3%, p = 0.002) and less residual ostial area stenosis of SB (9.2 ± 9.0% vs. 20.0 ±  
± 14.8%, p = 0.023), as assessed in vitro by micro-computed tomography. In a case-con-
trolled study, no adverse cardiac events were observed in the MRC group. The procedural suc-
cess was similar between MRC and MCS (100% vs. 95.2%, p = 0.548), but MRC had less 
residual ostial stenosis of the SB (8.7% ± 11.0% vs. 16.8% ± 11.2%, p = 0.008), lower pro-
cedural (33.3 ± 9.5 min vs. 46.7 ± 15.6 min, p = 0.001) and fluoroscopic (19.7 ± 4.9 min  
vs. 26.2 ± 7.1 min, p < 0.001) time, and less contrast use (114.3 ± 28.9 mL vs. 156.5 ± 56.4 mL,  
p = 0.002).
Conclusions: Mono-ring culotte stenting as compared to MCS is associated with better 
bifurcation stent morpho logy, less procedural complexity and residual ostial SB stenosis.  
(Cardiol J 2016; 23, 6: 673–684)
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Introduction
As firstly introduced by Chevalier et al. [1] 
for treatment of coronary bifurcation lesions, the 
culotte stenting underwent several modifications 
in order to improve the procedural safety and ef-
ficacy [2–4]. Nevertheless, the intrinsic procedural 
complexity, strict requirement of similar branch size 
and potential risks of acute branch loss, in-stent 
restenosis, or thrombosis remain the unsolved 
issues. Modified mini-culotte stenting (MCS) [2], 
to stent the side branch (SB) first with mini-
protrusion of the stent into the main vessel (MV) 
and to pre-imbed a balloon in the main branch (MB) 
for preventing branch loss, had lower requirement 
of similar branch size and was more safe and effi-
cient in treatment of coronary bifurcation lesions. 
However, if the branch diameter difference (BDD) 
between MB and SB is too significant, a stent 
under-expansion band (SUEB) will occur around the 
polygon of confluence, which will cause stent malap-
position around the bifurcated zone and residual 
obstruction at the ostium of the SB or MB, likewise 
increasing risks of in-stent restenosis or thrombosis 
[4]. In order to lessen SUEB and its related risks, 
we further modified the MCS to develop the double 
kissing MCS which was characterized by perform-
ing intermediate kissing balloon dilation (iKBD) 
prior to the MB stenting. Double kissing MCS 
has been shown to be more efficient in improving 
bifurcated stent morphology in bench testing and 
in reducing SB restenosis and target lesion/vessel 
revascularization in clinical application [4]. Despite 
this fact, there are numerous culotte-based stenting 
techniques available currently; the optimal one has 
not been established yet, particularly, the newly 
developed culotte techniques remain technically 
complex and procedurally challenging. Accordingly, 
we propose a simple culotte stenting technique, the 
mono-ring culotte stenting (MRC), which is charac-
terized by ex vivo wiring of the most proximal cell 
of the SB stent as an anchor to ensure a mono-ring 
result of the culotte stenting.
The present study was to test whether ex vivo 
mono-ring technique for the culotte stenting was 
technically feasible, and if MRC was superior to 
MCS in in vitro and in clinical treatment of coronary 
bifurcation lesions.
Methods
Stenting procedure for bench testing  
and clinical application
Mini-culotte stenting was performed accord-
ing to the description in previous studies [2–4]. 
The major steps of MRC were shown in Figure 1 
and described as follows: 1) wiring of the SB and 
MB, and pre-dilating the branches as necessary; 
2) extra-corporeal wiring of the most proximal cell 
of the SB stent with the hard end of the MB wire 
(as an anchoring wire) and crossing the SB wire 
via the central lumen of the SB stent, advancing 
the SB stent over the SB wire into the SB until the 
stent is anchored by the MB wire, then deploying 
the SB stent; 3) preserving the SB stent balloon 
and advancing another balloon over the MB wire 
to perform a sequential iKBD (inflating SB balloon 
first with higher pressure, followed by MB balloon 
inflating with lower pressure); 4) after removal of 
the two balloons and the SB wire, implanting the 
MB stent, and 5) rewiring the SB at a point close 
to the carina and then performing a final kissing 
balloon dilation (fKBD) with the two non-compliant 
balloons to finish the procedure. Figure 2 shows 
a representative case sample of bench testing or 
clinical practice with MRC.
Bench testing
Experimental protocol. Bench testing was 
performed on the coronary bifurcation model 
(Abbott Vascular Temecula), which was made from 
uniform silicone, according to Murray’s law. Test-
ing was repeated 5 times per category of distal 
bifurcation angulations of < 35°, 35–70°, > 70°, 
resulting in a total of 30 tests, 15 respectively for 
MRC and MCS, as shown in the flow chart (Fig. 3). 
For emulating steps of MRC or MCS and better 
showing the impact of BDD on the stenting results, 
open-cell designed stents (ExcelTM, JW Medical 
Inc., Shandong, China; ResoluteTM, Metronic Co., 
Minnesota, USA) of 2.5 mm and 3.5 mm were used 
to stent the SB and the MV/MB, respectively.
Quantitative and qualitative measure-
ments. The stenting procedures were observed 
visually and recorded with a high-resolution digital 
video recorder (L-1ex/TT02RX, ELMO, Japan); the 
final results were examined by micro-computed 
tomography (mCT) (SkyScan 1176, SkyScan, 
Belgium).
Quantitative analysis was performed with 
analytic software for mCT images (control software 
for SkyScan 1176) to measure the reference stent 
area (A1), the smallest stent area at the site of the 
stent-overlapped segment or polygon of confluence 
(A2), and branch ostial area (A3). Reference stent 
area for the MV, MB and SB was measured at the 
MV stent proximal edge, MB stent distal edge and 
SB stent distal edge, respectively. Branch ostial 
area was measured at the ostium of the MB and SB, 
respectively. The width of SUEB was defined as the 
distance from the superior border to inferior border 
of SUEB, longitudinally. The severity of SUEB, if 
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any in the stent-overlapped segment or polygon 
of confluence, was calculated with (A1 – A2) / 
/ A1 × 100% (Fig. 4). The residual ostial area 
stenosis (ROAS) for the SB or MB was calculated 
with (A1for MB/SB – A3for ostial MB/SB) / A1for MB/SB × 100%, 
as reported in previous study [5].
Qualitative analysis was performed to assess 
the final stent configuration based on the videos 
and mCT images. A 4-point system was developed 
for grading the bifurcated stent coverage (Fig. 5). 
Firstly, the grading region was set in the bifurcated 
and adjacent area and segmented into polygon of 
confluence, the carina, and segments 5 mm distal to 
the SB or MB ostium. Secondly, for describing stent 
deformation, the cell distribution was used as a ma-
jor index: even – similar cell size or the biggest cell 
size < 1.5 times of normal cell size; uneven – ir - 
regular strut distribution or the biggest cell size 
= 1.5–2.5 times of normal cell size; uncovered 
gap – severely irregular strut distribution or the 
biggest cell size (gap) > 2.5 times of normal cell 
size. Finally, bifurcation stent coverage (BSC) was 
graded by the scoring system: BSC-3 (complete 
BSC), no obvious uneven strut distribution noted 
in all segments; BSC-2 (slight incomplete BSC), 
uneven strut distribution noted in at least one 
segment; BSC-1 (moderate incomplete BSC), sig-
nificant uneven strut distribution; BSC-0 (severe 
incomplete BSC), stent-uncovered gaps.
Parameters and definitions. SUEB or ROAS 
was introduced to reflect stent expansion and 
BSC score to stent coverage. Usually, SUEB was 
located in the stent-overlapped segment or poly-
gon of confluence and defined as the stent lumen 
Figure 1. Major steps of mono-ring culotte stenting; A. Ex vivo wiring of the last cell of the side branch (SB) stent with 
the hard end of the main branch (MB) wire and crossing the SB wire via the central lumen of SB stent; B. Pinching 
the tails of SB and MB wire tightly, then inserting the stent into SB till it is unable to be pushed forward; C. Deploying 
the SB stent; D. Pushing the SB stent balloon deeply and inserting another through the last cell of SB stent; E. Pulling 
back the SB stent balloon and keeping it at the same level with the MB balloon; F, G. Dilating the SB balloon first and 
then dilating the MB balloon; H, I. Inserting and deploying the MB stent; J. Rewiring the SB at the point close to the 
carina; K. Performing final kissing balloon dilation with two non-compliant balloons; L. Final result.
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Figure 2A–H. Representative case samples of bench testing and clinical practice with mono-ring culotte stenting.
Figure 3. Study flow chart; DBA — distal bifurcation angulations; MCS — mini-culotte stenting; MRC — mono-ring 
culotte stenting.
Figure 4. Measurement for stent under-expansion band (SUEB) in vitro. The pictures represent mini-culotte stenting in 
bench testing. The cut line indicated the stent was cross-sectionally cut open at the inferior border of SUEB; A1 — ref-
erence stent area; A2 — the smallest stent area at the site of the stent-overlapped segment or polygon of confluence.
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under-expansion ≥ 20%, ROAS as the ostial area 
stenosis ≥ 70%, and incomplete BSC as BSC score 
£ 2, respectively.
Clinical application
Patient selection. From June 2014 to June 
2015, patients aged 18 years or older, with true 
coronary bifurcation lesions and treated with 
MRC, were considered eligible for enrollment. 
True coronary bifurcation lesions were referred 
to Medina’s bifurcation lesions (type 1,1,1; 0,1,1; 
1,0,1) [6, 7]. The diameter of the MB and SB by 
visual estimate should be ≥ 2.5 mm and ≥ 2.25 
mm, respectively. Patients, with ST-elevation acute 
myocardial infarction within 24 h, life expectancy 
< 1 year, or allergy to any of the drugs used 
(aspirin, clopidogrel, etc.), were excluded. All 
procedures performed in studies involving human 
participants were in accordance with the ethical 
standards of our institutional Research Committee 
and the 1964 Helsinki Declaration with its later 
amendments or comparable ethical standards. All 
patients gave written informed consent.
To test the clinical feasibility of MRC, the 
patients who underwent MCS from June 2014 to 
June 2015 were retrospectively screened in histori-
cal bifurcation percutaneous coronary intervention 
database of Fujian Medical University Union hospi-
tal. The inclusion and exclusion criteria were the 
same as for MRC. The eligible patients were used 
as control group.
Coronary angiography and analysis. Coro-
nary angiography was performed at baseline, at pro-
cedural end after intracoronary injection of 200 μg 
nitroglycerin. Quantitative coronary angiographic 
analysis was performed offline in the MV, MB and 
SB segments with a validated automatic edge-de-
tection system (QuantCor QCA System, Siemens 
AG, Erlangen, Germany). In the MV and SB seg-
ments, the major parameters of the minimal lumen 
diameter, percent diameter stenosis and reference 
vessel diameter were analyzed within the stent 
and the margins 5 mm proximal and distal to the 
stent edge [8].
Events and definitions. The technical or 
device success was defined as successful implanta-
tion of bifurcated stents with completion of fKBD 
without immediate complications, angiographic 
success as a minimal stenosis diameter reduction 
to < 20% with grade 3 Thrombolysis in Myocar-
dial Infarction (TIMI) flow in both branches post-
procedurally. Procedural success was defined as 
an angiographic success without in-hospital major 
cardiac adverse events of cardiac death, myocardial 
Figure 5. The 4-point scoring method for bifurcation stent coverage. Incomplete bifurcation stent coverage (BSC) was 
indicated as red arrow; A — severe incomplete BSC scored as 0; B — moderate BSC as 1; C — slight incomplete BSC 
as 2; D — complete BSC as 3.
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infarction, target vessel/lesion revascularization or 
in-stent thrombosis [9].
Non-Q-wave myocardial infarction was defined 
as cardiac troponin T/cardiac troponin I (cTnT/ 
/cTnI) increase to ≥ 5 times of the upper reference 
limit combined with clinical signs and without new 
onset of pathological Q waves; Q-wave myocar-
dial infarction as new development of pathological 
Q waves in two contiguous leads together with 
clinical signs. Target vessel/lesion revascularization 
was the repeat target vessel/lesion therapy either 
by percutaneous coronary intervention or surgery. 
In-stent thrombosis was diagnosed according to 
the Academic Research Consortium definition [10].
Statistical analysis
All analyses were performed using SPSS 
20.0 (SPSS Inc., Chicago, USA). Discrete or cat-
egorical variables are presented as numbers or 
percentages, continuous variables as mean ± 
standard deviation.
We used a method of propensity score match-
ing to reduce the treatment selection bias and the 
impact of potential confounding factors from the 
baseline lesion characteristics. The propensity 
score was calculated with a logistic regression 
model without regard to outcome variables. All 
bifurcation lesion factors that affect outcomes on 
univariate analysis were considered candidate vari-
ables. All variables with p < 0.20 were retained. 
The reliability of the model was evaluated using the 
Hosmer-Lemeshow test. According to the nearest 
matching algorithm, we created case-matched pairs 
without replacement at a 1:2 ratio.
To compare differences of the variables be-
tween the two groups, c2 or Fisher’s exact test was 
employed for the discrete variables and t-test for 
the continuous variables. All p values were 2-sided 
and the level of significance was 5%.
Results
Bench testing
The stent sorts, BDD (3.5 mm stent for MB, 
2.5 mm stent for SB) and branch distal angulation 
(53.2 ± 12.9° for MRC and 52.9 ± 10.6° for MCS, 
p > 0.05) were similar between MRC and MCS.
Table 1 shows the bifurcated stent morphology 
of MRC and MCS. Compared with MCS, MRC had 
lower incidence (0% vs. 53.3%, p = 0.002), less 
severity (7.9 ± 4.0% vs. 20.5 ± 5.9%, p < 0.001) 
and narrower width (0.05 ± 0.04 mm vs. 1.83 ± 
± 1.78 mm, p < 0.001) of SUEB; MRC had also 
lower incidence (0% vs. 33.3%, p = 0.042) and 
less severity (9.2 ± 9.0% vs. 20.0 ± 14.8%, p = 
= 0.023) of ROAS in the SB, with similar incidence 
and severity of ROAS in the MB. Moreover, the 
incidence of incomplete BSC was infrequent in the 
MRC group and similar as that of the MCS group 
(13.3% vs. 26.7%, p = 0.651).
Clinical application
Eligible patients comprised 23 patients treated 
with MRC and 119 patients with MCS. Based on 
a logistic regression analysis, 9 lesion charac-
teristics (Medina classification, SYNTAX score, 
BDD, the lesion length, minimal lumen diameter 
and diameter stenosis of MB and SB) were used 
Table 1. Comparison of the bifurcated stent morphologies.
Variables MRC (n = 15) MCS (n = 15) P 
SUEB:
  Incidence* 0 (0%) 8 (53.3%) 0.002
  Severity [%] 7.9 ± 4.0 20.5 ± 5.9 < 0.001
  Width [mm] 0.05 ± 0.04 1.83 ± 1.78 < 0.001
ROAS, SB:
  Incidence* 0 (0%) 5 (33.3%) 0.042
  Severity 9.2 ± 9.0 20.0 ± 14.8 0.023
ROAS, MB:
  Incidence 0 (0%) 0 (0%) 1.000
  Severity 4.7 ± 9.5 6.6 ± 7.8 0.551
Incidence of incomplete BSC* 2 (13.3%) 4 (26.7%) 0.651
*Fisher’s exact test; BSC — bifurcated stent coverage; MB — main branch; MCS — mini culotte stenting; MRC — mono-ring culotte stenting; 
ROAS — residual ostial area stenosis; SB — side branch; SUEB — stent under-expansion band
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for propensity score matching. Finally, 21 patients 
treated by MRC were matched with 42 patients 
by MCS.
Baseline characteristics
There were no differences in the baseline clini-
cal characteristics between the two groups neither 
before nor after propensity score matching. As for 
baseline lesion characteristics, BDD of the MB and 
SB was bigger (0.68 ± 0.41 mm vs. 0.51 ± 0.31 mm, 
p = 0.025) and the average SYNTAX score was signif-
icantly lower (20.7 ± 7.1 vs. 25.5 ± 10.1, p = 0.031) 
in the MRC group than in the MCS group. Addi-
tionally, there was a trend of more patients with 
Medina type (1, 1, 1) lesions in the MRC group 
(87.0% vs. 62.2% in the MCS group, p = 0.085). 
After propensity score matching, no difference was 
observed in each lesion variable (Table 2).
Procedural data
Before propensity score matching, there were 
no differences in interventional characteristics be-
tween the two groups except that the stent length 
of MB and SB was shorter in the MRC group than 
in the MCS group (MB: 27.7 ± 10.8 mm vs. 37.6 ± 
± 16.1 mm, p = 0.005; SB: 15.0 ± 6.2 mm vs. 
Table 2. Baseline clinical and lesion characteristics.
Variables Before propensity score matching After propensity score matching
MRC (n = 23) MCS (n = 119) P MRC (n = 21) MCS (n = 42) P 
Male 17 (73.9%) 97 (81.5%) 0.402 15 (71.4%) 31 (73.8%) 0.841
Age [years] 61.7 ± 10.0 64.1 ± 9.5 0.278 61.7 ± 10.3 64.2 ± 11.2 0.391
Hypertension 12 (52.2%) 68 (57.1%) 0.660 11 (52.4%) 21 (50.0%) 0.859
Diabetes mellitus 8 (34.7%) 35 (29.4%) 0.608 8 (38.1%) 16 (38.1%) 1.000
Hyper-cholesterol 9 (39.1%) 40 (33.6%) 0.610 8 (38.1%) 15 (35.7%) 0.853
Current smoking 7 (30.4%) 54 (45.4%) 0.185 7 (33.3%) 15 (35.7%) 0.852
Prior myocardial infarction* 4 (17.4%) 27 (22.7%) 0.784 3 (14.3%) 6 (14.3%) 1.000
Prior PCI* 2 (8.7%) 23 (19.3%) 0.368 2 (9.5%) 5 (11.9%) 1.000
Clinical presentation*: 0.248 1.000
Stable angina 3 (13.0%) 31 (26.1%) 2 (9.5%) 5 (11.9%)
Unstable angina 14 (60.9%) 71 (59.7%) 13 (61.9%) 26 (61.9%)
NSTEMI 5 (21.7%) 15 (12.6%) 5 (23.8%) 9 (21.4%)
STEMI 1 (4.4%) 2 (1.6%) 1 (4.8%) 2 (4.8%)
LVEF > 50%* 19 (82.6%) 94 (72.9%) 1.000 18 (85.7%) 36 (85.7%) 1.000
Lesion location*: 0.541 1.000
LM/LAD/LAX 7 (30.4%) 39 (32.8%) 6 (28.6%) 11 (26.2%)
LAD/Ds 13 (56.5%) 72 (60.5%) 12 (57.1%) 24 (57.1%)
LCX/OMs 2 (8.7%) 6 (5.0%) 2 (9.5%) 5 (11.9%)
RCA/PLA 1 (4.4%) 2 (1.7%) 1 (4.8%) 2 (4.8%)
Medina classifying*: 0.085 1.000
Type 1,1,1 20 (87.0%) 74 (62.2%) 18 (85.7%) 36 (85.7%)
Type 0,1,1 2 (8.7%) 29 (24.4%) 2 (9.5%) 4 (9.5%)
Type 1,0,1 1 (4.3%) 16 (13.4%) 1 (4.8%) 2 (4.8%)
Distal bifurcation angle > 70° 7 (30.4%) 39 (32.8%) 0.826 5 (23.8%) 10 (23.8%) 1.000
BDD [mm] 0.68 ± 0.41 0.51 ± 0.31 0.025 0.74 ± 0.39 0.65 ± 0.31 0.249
Calcification* 3 (13.0%) 10 (8.4%) 0.443 3 (14.3%) 6 (14.3%) 1.000
Tortuosity* 5 (21.7%) 16 (13.4%) 0.305 4 (19.0%) 8 (19.0%) 1.000
SyNTAX score 20.7 ± 7.1 25.5 ± 10.1 0.031 21.4 ± 7.0 20.2 ± 6.9 0.510
*Indicated by Fisher’s exact test. BDD — branch diameter difference between the main branch and side branch; Ds — diagonal branches;  
LAD — left anterior descending artery; LCX — left circumflex artery; LM — left main stem; LVEF — left ventricular ejection fraction; MCS —  
mini culotte stenting; MRC — mono-ring culotte stenting; NSTEMI — non-ST elevation myocardial infarction; OMs — obtuse marginal  
branches; PCI — percutaneous coronary intervention; PDA — posterior descending artery; PLA — posterolateral artery; RCA — right  
coronary artery; STEMI — ST elevation myocardial infarction
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21.1 ± 9.6 mm, p = 0.004). In the MCS group, 
fKBD was not complete in 2 patients and slow TIMI 
flow of SB occurred in 2 patients. No stent dislodge-
ment occurred and fKBD was complete in all pa-
tients in the MRC group. Both stenting techniques 
had similarly high rate of device, angiographic, 
and procedural success. No death, target vessel/ 
/lesion revascularization or acute stent thrombosis 
were observed in the MRC group. Only 4 (17.4%) 
patients had cTnT/cTnI > 5 times of upper refer-
ence limit, but all of them had no ischemic chest 
pain and/or new onset of pathological Q waves. 
Correspondently, there were 3 (2.5%) patients with 
non-Q-wave myocardial infarction and a trend of 
more patients (24.4%) with cTnT/cTnI > 5 times 
of upper reference limit in the MCS group. Death 
was observed in 1 patient from the MCS group, who 
was an 81-year-old male with a history of ischemia 
cardiomyopathy and low ejection fraction (21%); he 
died of acute heart failure 7 days after procedure. 
There was no difference in the in-hospital major 
cardiac adverse events between the two groups. 
Furthermore, MRC resulted in shorter procedural 
(33.4 ± 9.1 min vs. 45.7 ± 19.5 min, p = 0.004) 
and fluoroscopic time (19.3 ± 5.0 min vs. 25.1 ± 
± 8.9 min, p = 0.003), and less contrast media use 
(113.0 ± 29.3 mL vs. 155.6 ± 71.3 mL, p = 0.006) 
when compared with the other group.
After propensity score matching, all of tech-
nical parameters were adjusted. There were no 
differences in device, angiographic and procedural 
success, in-hospital major cardiac adverse events, 
or even patients with cTnT/cTnI > 5 times of upper 
reference limit. However, the advantage was that 
MRC reducing procedural (33.3 ± 9.5 min vs. 46.7 ± 
± 15.6 min, p = 0.001) and fluoroscopic time (19.7 ± 
± 4.9 min vs. 26.2 ± 7.1 min, p < 0.001), and less con-
trast media (114.3 ± 28.9 mL vs. 156.5 ± 56.4 mL, 
p = 0.002) was still preserved when compared with 
the MCS (Table 3).
QCA data
Before propensity score matching, imbalance 
was obvious between the two groups. At baseline, 
the lesion length of MV and SB were shorter in the 
MRC group than in the MCS group (MV: 27.0 ± 
± 11.3 mm vs. 34.1 ± 15.3, p = 0.038; SB: 13.1 ± 
± 5.7 mL vs. 18.5 ± 9.6 mL, p = 0.010). For the 
SB of MCS, especially minimal lumen diameter 
was smaller (0.59 ± 0.42 mm vs. 0.78 ± 0.33 mm, 
p = 0.044) and diameter stenosis was more severe 
(77.6% ± 14.8% vs. 70.6% ± 12.1%, p = 0.034) 
than those of MRC. Post-procedurally, both the 
diameter stenosis of MV/MB (6.6% ± 2.7% vs. 
8.8% ± 4.0%, p = 0.010) and SB (10.1% ± 5.3% 
vs. 19.3% ± 11.4%, p < 0.001) in the MRC group 
were lower than those in the MCS group. After 
propensity score matching, imbalance was adjusted 
among baseline quantitative analysis between 
the two groups. Post-procedurally, the diameter 
stenosis of MV/MB in the MRC group (7.8% ± 
± 5.9%) was similar to that in the MCS group 
(9.1% ± 5.1%, p = 0.382). However, by comparison 
with the MCS, the MRC significantly reduced the 
dia meter stenosis of SB (8.7% ± 11.0% vs. 16.8% ± 
± 11.2%, p = 0.008) (Table 4).
Discussion
An ideal 2-stent technique should be able to 
restore the bifurcation as close as possible to the 
native one, along with technical simplicity and 
procedural safety and efficacy. Our study demon-
strated that MRC was associated not only with 
better bifurcated stent expansion and coverage at 
the cost of minimal strut overlap in bench testing 
but also less procedural complexity and ostial SB 
residual stenosis in comparison with MCS in the 
case-controlled study.
What is new for MRC: Comparing with 
other related techniques
Mono-ring culotte stenting is different from 
Szabo or the flower petal techniques mainly in ex 
vivo wiring of the most proximal stent cell [11–18]. 
The original Szabo or modified flower petal tech-
niques utilized partial inflation of the SB stent to 
make a ‘flower petal’ and then to create a dual-wire 
stent-balloon unit prior to insertion. This step re-
quires creating a bulkier dual-wire stent-balloon unit 
and weakening the stent fixation. The former will 
impede subsequent advancement of the device and 
the latter cause stent dislodgement due to frictional 
drag or wire entanglement [13–15]. Conversely, 
MRC allows to wire ex vivo only one of the most 
proximal cells with the hard end of the MB wire 
instead of partially inflating the whole stent, thus 
preserving the stent fixation, and to create a simpler 
and smaller dual-wire stent system rather than 
a more complex and larger dual-wire balloon-stent 
unit, thereby making the device advancement much 
easier with lower risk of stent dislodgement.
Recently, Toth et al. [19] reported a single 
string technique that provided several unique 
advantages, especially minimal overlapping strut 
that other culotte stenting techniques did not 
possess. For this technique, the first critical step 
is accurate positioning of the SB stent to ensure 
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minimal protrusion into the MV, which is difficult 
due to complex bifurcation anatomy and continu-
ous heart beating. Even if accurate position of the 
SB stent is achieved, subsequent rewiring is still 
problematic due to the bifurcated anatomy and 
lesion complexity. Additionally, in vivo rewiring 
Table 3. Procedural data.
Variables Before propensity score matching After propensity score matching
MRC  
(n = 23)
MCS  
(n = 119)
P MRC  
(n = 21)
MCS  
(n = 42)
P 
Trans-radial 20 (87.0%) 94 (80.0%) 0.658 20 (95.2%) 39 (92.9%) 1.000
Sheath size: 0.495 0.832
6 F 5 (21.7%) 22 (18.5%) 5 (23.8%) 8 (19.0%)
7 F 18 (78.3%) 89 (74.8%) 16 (76.2%) 33 (78.6%)
8 F 0 (0.0%) 8 (6.7%) 0 (0.0%) 1 (2.4%)
Pre-dilation:
MB/MV 16 (69.6%) 63 (52.9%) 0.142 14 (66.7%) 27 (64.3%) 1.000
SB 9 (39.1%) 45 (37.8%) 0.905 8 (38.1%) 16 (38.1%) 1.000
Post-dilation*: 
MB/MV 23 (100.0%) 119 (100.0%) 1.000 21 (100.0%) 42 (100.0%) 1.000
SB 23 (100.0%) 117 (98.3%) 1.000 21 (100.0%) 41 (97.6%) 1.000
Final kissing balloon dilation* 23 (100%) 117 (98.3%) 1.000 21 (100.0%) 41 (97.6%) 1.000
Stent diameter:
MB/MV 3.18 ± 0.51 3.14 ± 0.48 0.654 3.23 ± 0.51 3.19 ± 0.51 0.788
SB 2.71 ± 0.39 2.88 ± 0.44 0.087 2.73 ± 0.40 2.80 ± 0.35 0.436
Total stent length [mm]:
MB/MV 27.7 ± 10.8 37.6 ± 16.1 0.005 28.5 ± 10.8 34.1 ± 17.3 0.184
SB 15.0 ± 6.2 21.1 ± 9.6 0.004 15.1 ± 6.4 16.2 ± 4.9 0.464
> 20% of residual diameter stenosis*:
MB/MV 0 (0%) 0 (0%) 1.000 0 (0%) 0 (0%) 1.000
SB 0 (0%) 2 (1.7%) 1.000 0 (0%) 1 (2.4%) 1.000
< 3 of TIMI flow*:
MB/MV 0 (0%) 0 (0.8%) 1.000 0 (0%) 0 (0%) 1.000
SB 0 (0%) 2 (1.7%) 1.000 0 (0%) 0 (0%) 1.000
Success rate*:
Technical 23 (100.0%) 116 (97.5%) 1.000 21 (100%) 41 (97.6%) 1.000
Angiographic 23 (100.0%) 117 (98.3%) 1.000 21 (100%) 41 (97.6%) 1.000
Procedural 23 (100.0%) 114 (95.8%) 1.000 21 (100%) 40 (95.2%) 0.548
Periprocedural myocardial infarction*:
Non-Q-wave* 0 (0%) 3 (2.5%) 1.000 0 (0%) 1 (2.4%) 1.000
Q-wave* 0 (0%) 0 (0%) 1.000 0 (0%) 0 (0%) 1.000
cTnT/cTnI > 5 × upper  
reference limit*
4 (17.4%) 29 (24.4%) 0.595 4 (19.0%) 9 (21.4%) 1.000
Acute in-stent thrombosis* 0 (0%) 0 (0%) 1.000 0 (0%) 0 (0%) 1.000
In-hospital major adverse  
cardiac events*
0 (0%) 4 (3.4%) 1.000 0 (0%) 1 (2.4%) 1.000
Procedural time§ [min] 33.4 ± 9.1 45.7 ± 19.5 0.004 33.3 ± 9.5 46.7 ± 15.6 0.001
Total fluoroscopy time [min] 19.3 ± 5.0 25.1 ± 8.9 0.003 19.7 ± 4.9 26.2 ± 7.1 < 0.001
Contrast volume [mL] 113.0 ± 29.3 155.6 ± 71.3 0.006 114.3 ± 28.9 156.5 ± 56.4 0.002
*Fisher’s exact test; §Indicates the time from “guidewire in” to “guidewire out”; cTnT/cTnI — cardiac troponin T/cardiac troponin I; MB — 
main branch; MCS — mini culotte stenting; MRC — mono-ring culotte stenting; MV — main vessel; SB — side branch; TIMI — Thrombolysis 
in Myocardial Infarction
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of a single cell needs an experienced hand and 
may dissect the MB or enlarge the MB dissection 
created by pre-dilation, or even cause disastrous 
MB occlusion. Unlike the single string technique, 
MRC wires the last stent cell ex vivo, which is 
surprisingly easy (Supplementary Video 1 — see 
journal website). Importantly, ex vivo wiring can 
reliably avoid the problems associated with in vivo 
wiring, leading to less technical complexity and 
better procedural safety.
How to properly perform MRC:  
Tricks and tips
As shown in Figure 1, MRC was characterized 
by ex vivo wiring of the last proximal cell of the 
SB stent as an anchor to optimize stent protru-
sion into the MV. There are three key steps for 
the procedure: ex vivo wiring and anchoring of 
a proximal cell of the SB stent, inserting the dual-
wire stent unit into the target site and optimizing 
the SB stent protrusion and resultant bifurcated 
stent configuration.
Ex vivo wiring and anchoring of the most 
proximal stent cell can be readily achieved by using 
the hard end of the MB wire. We recommend this 
step being done by a younger interventionist with 
good eyesight. Advancing of the dual-wire stent 
unit into the target site may be somehow difficult. 
Lower or higher resistance will be encountered 
during device insertion; occasionally there is great 
difficulty in advancing the unit mainly due to wire 
entanglement. It is noteworthy that any rough ac-
tion should be abandoned in processes of ex vivo 
wiring of the most proximal stent cell and push-
Table 4. Quantitative coronary analysis at baseline and immediate post-procedurally.
Variables MV/MB SB
MRC MCS P MRC MCS P 
Before propensity score matching (n = 23 in group MRC; n = 119 in group MCS)
Baseline
Lesion length [mm] 27.0 ± 11.3 34.1 ± 15.3 0.038 13.1 ± 5.7 18.5 ± 9.6 0.010
Reference vessel  
diameter [mm]
3.35 ± 0.57 3.15 ± 0.49 0.078 2.67 ± 0.39 2.63 ± 0.44 0.708
Minimal lumen  
diameter [mm]
0.72 ± 0.35 0.54 ± 0.56 0.153 0.78 ± 0.33 0.59 ± 0.42 0.044
Diameter stenosis [%] 78.1 ± 11.2 83.2 ± 16.2 0.149 70.6 ± 12.1 77.6 ± 14.8 0.034
Post-procedure
Reference vessel  
diameter [mm]
3.44 ± 0.64 3.27 ± 0.51 0.163 2.78 ± 0.44 2.85 ± 0.43 0.462
Minimal lumen  
diameter [mm]
3.21 ± 0.58 2.99 ± 0.51 0.058 2.50 ± 0.42 2.31 ± 0.49 0.084
Diameter stenosis [%] 6.6 ± 2.7 8.8 ± 4.0 0.010 10.1 ± 5.3 19.3 ± 11.4 <0.001
After propensity score matching (n = 21 in group MRC; n = 42 in group MCS)
Baseline
Lesion length [mm] 27.6 ± 11.2 30.5 ± 16.1 0.464 13.4 ± 5.9 13.5 ± 5.2 1.000
Reference vessel  
diameter [mm]
3.44 ± 0.62 3.25 ± 0.55 0.209 2.69 ± 0.33 2.60 ± 0.44 0.407
Minimal lumen  
diameter [mm]
0.70 ± 0.32 0.69 ± 0.55 0.934 0.76 ± 0.34 0.70 ± 0.41 0.571
Diameter stenosis [%] 79.6 ± 10.4 78.1 ± 17.4 0.713 71.7 ± 11.8 72.5 ± 15.5 0.832
Post-procedure
Reference vessel  
diameter [mm]
3.48 ± 0.61 3.31 ± 0.50 0.243 2.77 ± 0.42 2.76 ± 0.33 0.951
Minimal lumen  
diameter [mm]
3.19 ± 0.52 3.02 ± 0.53 0.218 2.52 ± 0.44 2.31 ± 0.49 0.111
Diameter stenosis [%] 7.8 ± 5.9 9.1 ± 5.1 0.382 8.7 ± 11.0 16.8 ± 11.2 0.008
MB — main branch; MCS — mini-culotte stenting; MRC — mono-ring culotte stenting; MV — main vessel; SB — side branch
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ing the SB stent as it may result in stent damage 
and destroy the stent fixation so that the SB stent 
dislodges. To avoid such situations, selecting 
a bigger guiding catheter, full flaring of the proximal 
cell, using a hydrophilic coated and softer wire, 
avoiding too much wire rotation and separating the 
two twisted wires with a predilating balloon prior 
to SB stenting, or fully predilating of lesions, will 
be helpful. Actually, optimizing the stent protru-
sion and configuration is composed of two vital 
steps — minimizing stent protrusion into the MV 
and maintaining the ostial SB stent configuration 
without distortion. Anchoring the proximal cell of 
the SB stent automatically leads to minimizing the 
SB stent protrusion, while performing a sequen-
tial iKBD is essential for preventing the ostial SB 
stent from distortion, which can be done by first 
inflation of the SB balloon with higher pressure to 
fix the ostial SB stent, followed by inflation of the 
MB balloon with lower pressure to fully open the 
anchored cell.
Outcomes of MRC: Comparing with MCS
Culotte-based stenting techniques, particu-
larly MCS, have regained enthusiasm in interven-
tion of coronary bifurcation lesions because of 
several modifications that enhance the procedural 
safety and efficacy. Nevertheless, these techniques 
remain technically complex. By owning 3 key 
technical modifications, whether MRC can more 
effectively solve the problems associated with 
culotte-based stenting and translate into improve-
ment of clinical outcomes warrants to be further 
tested.
In the present study, as compared to MCS, 
bench testing showed that MRC was associated 
with better stent configuration in terms of stent ex-
pansion and coverage in polygon of confluence and 
adjacent area (SB ostium, MB ostium, or carina). 
Meanwhile, the clinical case-controlled study also 
demonstrated that MRC not only had the same high 
rate of angiographic and procedural success as MCS 
but also effectively avoided stent advancing diffi-
culty and stent dislodgement, as using Szabo and 
its modified technique, and technical challenges for 
in vivo wiring a single cell, as using single string 
technique [11–19]. Importantly, MRC significantly 
reduced procedural time, fluoroscopic time and 
contrast consumption, as well as residual stenosis 
of the ostial SB with good procedural safety.
Limitations of the study
In bench testing, despite considering greater 
BDD between MB and SB, a silicon model may not 
exactly represent anatomy of coronary bifurcation 
lesions in clinical scenarios, therefore the find-
ings should be explained with caution. In a clinical 
case-controlled study, although a propensity score 
matching was used to adjust anatomic differences 
of coronary bifurcation lesions, we cannot utterly 
exclude other hidden confounders (i.e. physician’s 
preference), and only a small number of case pairs 
with short-term outcomes were included into 
analysis, which also cannot completely avoid bias. 
Therefore, a controlled, randomized, larger popula-
tion study is warranted for further confirming the 
long-term efficacy of MRC.
Conclusions
In conclusion, as compared to MCS, our study 
demonstrated that MRC was associated with bet-
ter bifurcated stent configuration in bench testing 
and less procedural complexity, as well as residual 
ostial stenosis of the SB in clinical application, 
indicating that ex vivo mono-ring technique was 
feasible for simplification of culotte stenting.
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